Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 May;1(1):34-42.
doi: 10.18632/oncotarget.106.

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome

Emmanuel Raffoux  1 , Audrey Cras  2 , Christian Recher  3 , Pierre-Yves Boëlle  4 , Adrienne de Labarthe  1 , Pascal Turlure  5 , Jean-Pierre Marolleau  6 , Oumedaly Reman  7 , Claude Gardin  8 , Maud Victor  2 , Sébastien Maury  9 , Philippe Rousselot  10 , Jean-Valère Malfuson  11 , Odile Maarek  1 , Marie-Thérèse Daniel  1 , Pierre Fenaux  8 , Laurent Degos  1 , Christine Chomienne  2 , Sylvie Chevret  12 , Hervé Dombret  1
Affiliations
Clinical Trial

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome

Emmanuel Raffoux et al. Oncotarget. 2010 May.

Abstract

In this Phase 2 study, we evaluated the efficacy of combination of 5-azacitidine (AZA), valproic acid (VPA), and all-trans retinoic acid (ATRA) in patients with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Treatment consisted of six cycles of AZA and VPA for 7 days, followed by ATRA for 21 days. Sixty-five patients were enrolled (median age, 72 years; 55 AML including 13 relapsed/refractory patients, 10 MDS; 30 unfavorable karyotypes). Best responses included 14 CR and 3 PR (26%), 75% of the responders and 36% of the non-responders achieving an erythroid response. Median overall survival (OS) was 12.4 months. Untreated patients had a longer OS than relapsed/refractory patients. In patients who fulfilled the 6 planned cycles, OS did not appear to depend on CR/PR achievement, suggesting that stable disease while on-treatment would be a surrogate for survival with this approach. During therapy, early platelet response and demethylation of the FZD9, ALOX12, HPN, and CALCA genes were associated with clinical response. Finally, there was no evidence for the restoration of an ATRA-induced differentiation during therapy. Epigenetic modulation deserves prospective comparisons to conventional care in patients with high-risk AML, at least in those presenting previously untreated disease and low blast count.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kinetics of peripheral blood neutrophil count, platelet count, and hemoglobin level during the treatment period. The evolution of peripheral blood neutrophil count (/mm3), platelet count (/mm3), and hemoglobin level (g/dL) is shown in the 34 patients who may receive the planned 6 treatment cycles, according to the response (15 CR + PR patients versus 19 non-responding patients).
Fig. 2
Fig. 2. Overall survival
(A) OS from study inclusion according to the three eligibility subsets. OS was significantly shorter in patients relapsing after prior intensive chemotherapy (subset 2) than in naïve patients with either AML (subset 1) or high-risk MDS (subset 3) (P= 0.0024). (B) OS following the 6-month evaluation according to the response observed at 6 months. In the 34 patients who received the 6 planned cycles, OS after the 6-month evaluation was not significantly different between responding (N= 15) and non-responding (N= 19) patients.
See this image and copyright information in PMC

References

    1. Herman JG, Baylin SB. Mechanisms of disease: gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042–2054. - PubMed
    1. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429–2440. - PubMed
    1. Sudan N, Rossetti JM, Shadduck RK, Latsko J, Lech JA, Kaplan RB, Kennedy M, Gryn JF, Faroun Y, Lister J. Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer. 2006;107:1839–1843. - PubMed
    1. Cashen AF, Schiller GJ, O'Donnell MR, Larsen JS, Baranwal A, DiPersio JF. Preliminary results of a multicenter Phase II trial of 5-day decitabine as front-line therapy for elderly patients with acute myeloid leukemia. Blood. 2008;112:560. ASH Meeting Abstracts.
    1. Lübbert M, Schmid M, Rüter B, Germing U, Rethwisch V, Ganser A, Platzbecker U, Galm O, Brugger W, Wijermans PW, Schmoor C, Döhner H. Continued treatment with an outpatient maintenance schedule of decitabine in older AML patients ineligible for induction chemotherapy: results of the 00331 Phase II multicenter trial. Blood. 2008;112:2965. ASH Meeting Abstracts.

Publication types

MeSH terms